A review on newly approved PARP inhibitors: Talazoparib and Olaparib

A review on newly approved PARP inhibitors: Talazoparib and Olaparib

This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.

Détails bibliographiques
Auteur principal: Karim, Azrin
Autres auteurs: Islam, Farzana
Format: Project report
Langue:English
Publié: Brac University 2024
Sujets:
PARP inhibitors
Olaparib
Talazoparib
DNA damage repair
DDR signaling pathway
Homologous recombination repair
Prostate cancer
Ovarian cancer
Metastatic breast cancer
BRCA mutations
Cancer > Treatment > Genetic aspects.
DNA repair.
NAD-ADP-ribosyltransferase > Inhibitors > Therapeutic use.
Antineoplastic agents.
Accès en ligne:http://hdl.handle.net/10361/24372

Internet

http://hdl.handle.net/10361/24372

Documents similaires